Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Biotechnology Industry — Last 7 Days

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume

Oruka Therapeutics, Inc. (ORKA)

Agarwal Arjun — Senior Vice President, Finance
Sep 21, 2026
Sale
Shares
533
Price
$95.75
Total Value
$51.03K
Shares Held After
14,219
% of Holdings
3.6%

Oruka Therapeutics, Inc. (ORKA)

Quinlan Paul T — General Counsel
Sep 21, 2026
Sale
Shares
2,667
Price
$95.31
Total Value
$254.20K
Shares Held After
29,995
% of Holdings
8.2%

Oruka Therapeutics, Inc. (ORKA)

Quinlan Paul T — General Counsel
Sep 21, 2026
Sale
Shares
601
Price
$94.44
Total Value
$56.76K
Shares Held After
32,662
% of Holdings
1.8%

Oruka Therapeutics, Inc. (ORKA)

Quinlan Paul T — General Counsel
Sep 21, 2026
Sale
Shares
3,832
Price
$93.32
Total Value
$357.59K
Shares Held After
33,263
% of Holdings
10.3%

Oruka Therapeutics, Inc. (ORKA)

Quinlan Paul T — General Counsel
Sep 21, 2026
Sale
Shares
2,900
Price
$92.37
Total Value
$267.87K
Shares Held After
37,095
% of Holdings
7.3%
Sep 18, 2026
Sale
Shares
9,132
Price
$3.24
Total Value
$29.55K
Shares Held After
25,384
% of Holdings
26.5%

Bolt Biotherapeutics, Inc. (BOLT)

Nemec Sarah — Senior VP, Finance and PAO
Sep 18, 2026
Sale
Shares
4,077
Price
$3.24
Total Value
$13.19K
Shares Held After
17,082
% of Holdings
19.3%

Bolt Biotherapeutics, Inc. (BOLT)

Yonehiro Grant — Chief Operating Officer
Sep 18, 2026
Sale
Shares
6,850
Price
$3.24
Total Value
$22.17K
Shares Held After
17,269
% of Holdings
28.4%
Sep 18, 2026
Sale
Shares
160
Price
$498.25
Total Value
$79.72K
Shares Held After
324,443
% of Holdings
0.0%
Sep 18, 2026
Sale
Shares
277
Price
$496.64
Total Value
$137.57K
Shares Held After
324,603
% of Holdings
0.1%
Sep 18, 2026
Sale
Shares
2,330
Price
$495.66
Total Value
$1.15M
Shares Held After
324,880
% of Holdings
0.7%
Sep 18, 2026
Sale
Shares
4,269
Price
$494.70
Total Value
$2.11M
Shares Held After
327,210
% of Holdings
1.3%
Sep 18, 2026
Sale
Shares
2,216
Price
$493.78
Total Value
$1.09M
Shares Held After
331,479
% of Holdings
0.7%
Sep 18, 2026
Sale
Shares
248
Price
$492.91
Total Value
$122.24K
Shares Held After
333,695
% of Holdings
0.1%

NovaBridge Biosciences (NBP)

Dennis Phillip Andrew — Chief Medical Officer
Sep 18, 2026
Sale
Shares
8,209
Price
$0.71
Total Value
$5.83K
Shares Held After
173,427
% of Holdings
4.5%

BioNTech SE (BNTX)

Sahin Ugur — Chief Executive Officer
Sep 18, 2026
Sale
Shares
30,000
Price
$96.22
Total Value
$2.89M
Shares Held After
489,209
% of Holdings
5.8%

Harmony Biosciences Holdings, Inc. (HRMY)

Budur Kumar — CHIEF MEDICAL OFFICER
Sep 18, 2026
Sale
Shares
35,852
Price
$43.05
Total Value
$1.54M
Shares Held After
13,115
% of Holdings
73.2%
Sep 18, 2026
Sale
Shares
7,837
Price
$16.71
Total Value
$130.96K
Shares Held After
271,765
% of Holdings
2.8%

CRESCENT BIOPHARMA, INC. (CBIO)

McNeill Jonathan — President and COO
Sep 18, 2026
Sale
Shares
3,839
Price
$16.71
Total Value
$64.15K
Shares Held After
134,588
% of Holdings
2.8%
Sep 17, 2026
Sale
Shares
33,800
Price
$7.46
Total Value
$252.15K
Shares Held After
3,448,812
% of Holdings
1.0%
Sep 17, 2026
Sale
Shares
3,415,011
Price
$6.32
Total Value
$21.58M
Shares Held After
3,482,612
% of Holdings
49.5%
Sep 17, 2026
Sale
Shares
13,679
Price
$57.09
Total Value
$780.94K
Shares Held After
16,637
% of Holdings
45.1%
Sep 17, 2026
Sale
Shares
1,279
Price
$69.57
Total Value
$88.98K
Shares Held After
495,686
% of Holdings
0.3%
Sep 17, 2026
Sale
Shares
8,721
Price
$69.01
Total Value
$601.87K
Shares Held After
496,965
% of Holdings
1.7%
Sep 17, 2026
Sale
Shares
6,545
Price
$3.32
Total Value
$21.72K
Shares Held After
34,516
% of Holdings
15.9%

Bolt Biotherapeutics, Inc. (BOLT)

Nemec Sarah — Senior VP, Finance and PAO
Sep 17, 2026
Sale
Shares
2,922
Price
$3.32
Total Value
$9.70K
Shares Held After
21,159
% of Holdings
12.1%

Bolt Biotherapeutics, Inc. (BOLT)

Yonehiro Grant — Chief Operating Officer
Sep 17, 2026
Sale
Shares
4,909
Price
$3.32
Total Value
$16.29K
Shares Held After
24,119
% of Holdings
16.9%

Enliven Therapeutics, Inc. (ELVN)

Collins Helen Louise — CHIEF MEDICAL OFFICER
Sep 17, 2026
Sale
Shares
240
Price
$51.48
Total Value
$12.36K
Shares Held After
25,000
% of Holdings
1.0%

Enliven Therapeutics, Inc. (ELVN)

Collins Helen Louise — CHIEF MEDICAL OFFICER
Sep 17, 2026
Sale
Shares
1,844
Price
$50.71
Total Value
$93.51K
Shares Held After
25,240
% of Holdings
6.8%

Enliven Therapeutics, Inc. (ELVN)

Collins Helen Louise — CHIEF MEDICAL OFFICER
Sep 17, 2026
Sale
Shares
2,916
Price
$50.03
Total Value
$145.89K
Shares Held After
27,084
% of Holdings
9.7%

Enliven Therapeutics, Inc. (ELVN)

Hohl Benjamin — CHIEF FINANCIAL OFFICER
Sep 17, 2026
Sale
Shares
289
Price
$51.49
Total Value
$14.88K
Shares Held After
38,000
% of Holdings
0.8%

Enliven Therapeutics, Inc. (ELVN)

Hohl Benjamin — CHIEF FINANCIAL OFFICER
Sep 17, 2026
Sale
Shares
2,194
Price
$50.72
Total Value
$111.27K
Shares Held After
38,289
% of Holdings
5.4%

Enliven Therapeutics, Inc. (ELVN)

Hohl Benjamin — CHIEF FINANCIAL OFFICER
Sep 17, 2026
Sale
Shares
3,535
Price
$50.03
Total Value
$176.85K
Shares Held After
40,483
% of Holdings
8.0%

Pharvaris N.V. (PHVS)

Lu Peng — President
Sep 17, 2026
Sale
Shares
100,000
Price
$35.00
Total Value
$3.50M
Shares Held After
64,953
% of Holdings
60.6%
Shares
200,000
Price
$35.00
Total Value
$7.00M
Shares Held After
115,167
% of Holdings
63.5%

Pharvaris N.V. (PHVS)

Lesage Anne — Chief Early Development
Sep 17, 2026
Sale
Shares
20,000
Price
$38.27
Total Value
$765.47K
Shares Held After
73,969
% of Holdings
21.3%

Pharvaris N.V. (PHVS)

Glassman Robert — Director
Sep 17, 2026
Sale
Shares
14,493
Price
$38.56
Total Value
$558.81K
Shares Held After
10,500
% of Holdings
58.0%

Pharvaris N.V. (PHVS)

Bjork Elisabeth — Director
Sep 17, 2026
Sale
Shares
52,500
Price
$37.89
Total Value
$1.99M
Shares Held After
15,167
% of Holdings
77.6%
Sep 17, 2026
Sale
Shares
160
Price
$501.60
Total Value
$80.26K
Shares Held After
324,443
% of Holdings
0.0%
Sep 17, 2026
Sale
Shares
468
Price
$500.09
Total Value
$234.04K
Shares Held After
324,603
% of Holdings
0.1%
Sep 17, 2026
Sale
Shares
332
Price
$499.10
Total Value
$165.70K
Shares Held After
325,071
% of Holdings
0.1%
Sep 17, 2026
Sale
Shares
151
Price
$497.79
Total Value
$75.17K
Shares Held After
325,403
% of Holdings
0.0%
Sep 17, 2026
Sale
Shares
1,953
Price
$497.17
Total Value
$970.98K
Shares Held After
325,554
% of Holdings
0.6%
Sep 17, 2026
Sale
Shares
2,182
Price
$496.21
Total Value
$1.08M
Shares Held After
327,507
% of Holdings
0.7%
Sep 17, 2026
Sale
Shares
1,905
Price
$495.11
Total Value
$943.18K
Shares Held After
329,689
% of Holdings
0.6%
Sep 17, 2026
Sale
Shares
1,750
Price
$494.34
Total Value
$865.10K
Shares Held After
331,594
% of Holdings
0.5%
Sep 17, 2026
Sale
Shares
599
Price
$493.22
Total Value
$295.44K
Shares Held After
333,344
% of Holdings
0.2%

BioNTech SE (BNTX)

Sahin Ugur — Chief Executive Officer
Sep 17, 2026
Sale
Shares
34,000
Price
$98.60
Total Value
$3.35M
Shares Held After
519,209
% of Holdings
6.1%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP&GENERAL COUNSEL
Sep 17, 2026
Sale
Shares
320
Price
$501.58
Total Value
$160.51K
Shares Held After
45,172
% of Holdings
0.7%

UNITED THERAPEUTICS Corp (UTHR)

MAHON PAUL A — EVP&GENERAL COUNSEL
Sep 17, 2026
Sale
Shares
125
Price
$500.80
Total Value
$62.60K
Shares Held After
45,492
% of Holdings
0.3%
Version: v26.9.1